Authors

• Takayuki Hamano (ORCID: https://orcid.org/0000-0002-2100-9106)
• Takahisa Kasugai (ORCID: https://orcid.org/0009-0000-4445-3878)
• Tatsuya Tomonari
• Kodai Suzuki (ORCID: https://orcid.org/0000-0003-1861-7394)
• Masashi Mizuno (ORCID: https://orcid.org/0000-0003-3235-6880)
• Yuki Miyaguchi (ORCID: https://orcid.org/0009-0009-3188-4500)
• Miho Murashima (ORCID: https://orcid.org/0000-0002-2923-0438)
• Maki Hiratsuka (ORCID: https://orcid.org/0000-0002-8974-3921)
• Minamo Ono
• Tomohiro Tanaka (ORCID: https://orcid.org/0000-0002-6212-4274)

Institutions

• Nagoya City University (JP)
• Nagoya Medical Center (JP)
• Kindai University (JP)
• The University of Osaka (JP)

Publication Details

Journal

Journal of Diabetes Investigation

Published

2025-11-12

DOI

https://doi.org/10.1111/jdi.70189

Primary Topic

Diabetes Treatment and Management

Type

article

Field-Weighted Citation Impact

0.00

Funders

• American Society of Nephrology
• Eli Lilly and Company
• AstraZeneca
• Kowa Company
• Kissei
• Torii Pharmaceutical
• Boehringer Ingelheim Japan
• Astellas Pharma
• Mitsubishi Tanabe Pharma Corporation
• Ono Pharmaceutical
• Eli Lilly Japan